Thomas A.Briggs (Tom)

Partner

San Diego + 1.858.314.1164

Connect:

Share

Tom Briggs negotiates technology-based transactions, such as licenses, strategic alliances, joint ventures, mergers, acquisitions, and divestitures, where intellectual property is the focal point. Tom also negotiates agreements that involve the transfer, protection, or sharing of IP or of new products and services, such as for distribution, manufacturing, supply, software and services, joint development, sponsored research, clinical trials, employee IP rights, and consulting.

Tom is the Firm's head of transactions for California, where he serves as cross-practice leadership of lawyers in the M&A, private equity, and financial market practices and others handling transactional work, including in the IP, energy, real estate, and health care practices. He was a founder of Jones Day's IP Transactions team.

Tom has extensive experience representing clients in cross-border transactions, particularly between the United States, China, Japan, and Europe. Clients include Bunge, EagleTree Capital, Genomatica, Idemitsu Kosan, Incyte, Ishihara Sangyo Kaisha, Koch, Organon, P&G, Polaris, and Shanghai Junshi.

In helping clients with their technology transactions, Tom draws upon a rare combination of work experiences. He is a patent lawyer who has litigated cases involving infringement, misappropriation, and noncompetition and has prosecuted patent and trademark registrations. He has served as chief intellectual property officer and assistant general counsel of M.A. Hanna Company (now PolyOne Corporation). He also spent 10 years as a practicing chemical engineer and plant supervisor with Union Carbide/Praxair before his career as a lawyer. Tom leverages his engineering career and scientific training by focusing on transactions that involve pharmaceuticals, biotech, medical devices, food, agriculture, environment, sustainability, fermentation, industrial chemicals, semiconductors, software, polymers, steel, and oil and gas.

Experience

  • Reneo Pharmaceuticals announces reverse merger with OnKureJones Day represented Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) in an all-stock reverse merger between Reneo and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company valued at $170 million that is focused on the development of novel precision medicines in oncology.
  • Chevron and MOECO agree to explore advanced closed loop geothermal pilot in Hokkaido, JapanJones Day advised Chevron New Energies on its agreement with Mitsui Oil Exploration Co., Ltd (MOECO) to proceed with the pilot testing of advanced geothermal technology, specifically advanced closed loop (ACL) technology.
  • Genomatica grants license to make bio-based, sustainable BDO to Hyosung TNC for manufacture of bio-based SpandexJones Day represented Genomatica, Inc. in its license to Hyosung TNC under Genomatica's proprietary, bio-based process and engineered microorganisms to manufacture 1,4 butanediol (BDO) by fermentation of sugar sources.
  • Junshi grants exclusive rights to Dr. Reddy's for toripalimab cancer treatmentJones Day represented Shanghai Junshi Biosciences Co., Ltd. ("Junshi") in its grant of exclusive rights related to the development and commercialization of toripalimab, an anti-PD1 monoclonal antibody, to Dr. Reddy's Laboratories for the territory of Latin America, India, South Africa, and an option to expand the territory to include Australia and New Zealand and potential other countries.
  • Junshi Biosciences forms joint venture with Rxilient Biotech to develop and commercialize toripalimab in Southeast AsiaJones Day advised Junshi Biosciences in the formation of a joint venture company, Excellmab, with Rxilient Biotech to develop and commercialize toripalimab, an anti-PD-1 monoclonal antibody drug, in nine Southeast Asian countries.
  • Junshi grants license to Hikma for toripalimab in Middle East and North AfricaJones Day represented Shanghai Junshi Biosciences Co., Ltd. in its license agreement with Hikma Pharmaceuticals PLC for the development and commercialization of toripalimab, an anti-PD1 monoclonal antibody, in the Middle East and North Africa.
  • Incyte grants rights to CMS for ruxolitnib cream in China and Southeast AsiaJones Day represented Incyte Corporation in its Collaboration and License Agreement with CMS Aesthetics Limited for the development and commercialization of ruxolitinib cream, a novel cream formulation of Incyte’s selective JAK inhibitor ruxolitinib, for the treatment of autoimmune and inflammatory dermatologic diseases in Greater China and certain countries in Southeast Asia. 
  • Nasco sells Whirl-Pak®Jones Day advised EagleTree Capital and its portfolio company, Nasco, in the sale of Whirl-Pak®, a leading provider of sterilized sampling and testing solutions including its line of write-on, stand-up, filter and other specialty single-use sterilized sampling bags and accessories, to Filtration Group, an affiliate of Madison Industries.
  • EagleTree Capital acquires The Channel CompanyJones Day advised EagleTree Capital in the acquisition and financing of The Channel Company, a leading provider of business services for the IT sector, from Stone-Goff Partners.
  • Incyte and Innocare announce collaboration and license agreement for Tafasitimab in Greater ChinaJones Day represents Incyte Corporation in an exclusive license out of rights to conduct clinical trials, seek regulatory approval, and commercialize products containing Tafasitamab, an anti-CD19 monoclonal antibody, in Greater China.
  • Cooper Tire & Rubber sold to The Goodyear Tire & Rubber Company for approximately $2.5 billion enterprise valueJones Day advised Cooper Tire & Rubber Company in its $2.5 billion sale to The Goodyear Tire & Rubber Company.
  • Xact Data Discovery sells company to Aquiline Capital PartnersJones Day represented Xact Data Discovery, a leading international provider of eDiscovery, data management, and managed review services for major law firms and corporations and portfolio company of JLL Partners, in connection with its acquisition by Aquiline Capital Partners LLC, a New York-based private equity firm.
  • Polaris teams up with Zero Motorcycles to electrify ATVs and snowmobilesJones Day represented Polaris Industries Inc., OEM of off-road vehicles/ATVs, snowmobiles, motorcycles and boats sold under the POLARIS, RZR, RANGER, GENERAL, SPORTSMAN, INDIAN, and HURRICANE brands, among others, on its entry into a joint development, licensing, and services relationship with Zero Motorcycles, a global leader in electronic motorcycle powertrains and technology.
  • Junshi Biosciences collaborates with Coherus Biosciences to co-develop anti-PD-1 antibody and grants options for anti-TIGIT and IL-2 cytokine moleculesJones Day represented Junshi Biosciences in its license out of technology and IP related to an anti-PD-1 antibody known as Toripalimab and options for two other molecules.
  • Micreos teams up with L'Oréal for skin care products containing endolysinsJones Day represented Micreos Human Health B.V. in its license out to L'Oréal of endolysin technology that targets harmful skin bacteria while preserving useful bacteria for L'Oréal's use worldwide in skin care products for cosmetic applications.
  • Furukawa Electric and Superior Essex global joint venture finalizedJones Day advised Furukawa Electric Co., Ltd. in its finalization of a global joint venture with Superior Essex Inc.
  • Junshi and Revitope team up for TEAC molecules through development, license, and equityJones Day represented Shanghai Junshi Biosciences Co., Ltd. in a research collaboration and license agreement with Revitope Oncology Inc. and its subsidiary to collaborate in the research and development of T-cell engaging cancer immunotherapies that utilize Junshi's antibody technology platform with Revitope's proprietary dual-antigen targeting technology platform.
  • Junshi and Lilly to develop and commercialize antibodies for prevention and treatment of COVID-19 coronavirusJones Day represented Shanghai Junshi Biosciences Co., Ltd. in its strategic collaboration and license agreement with Eli Lilly and Company for the development, manufacturing, and commercialization of two antibodies for the prevention and treatment of the COVID-19 SARS-CoV-2 novel coronavirus.
  • Athersys completes $57.6 million public offering of Common StockJones Day represented Athersys, Inc., a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life, in connection with the $57.6 million underwritten public offering of 25,587,500 shares of Common Stock.
  • PGT Innovations acquires NewSouth Window SolutionsJones Day advised PGT Innovations, Inc., a national leader in premium windows and doors, including impact-resistant products, in connection with its $92 million cash acquisition of NewSouth Window Solutions, subject to adjustments.
    • View All

    December 2023 Alert

    EU Strikes Political Deal on Landmark Artificial Intelligence Act

    October 2023 Alert

    President Biden Issues Executive Order on "Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence"

    August 2022 Commentary

    CRISPR Technology in the Agricultural Industry: Patent and Regulatory Updates

    Additional Speaking Engagements

    • November 7, 2018
      Licensing Fundamentals for Business Executives and Startups
    • May 6, 2015
      Licensing Fundamentals - for Business Executives and Startups, CONNECT Frameworks Workshop
    • May 7, 2014
      Licensing Fundamentals - for Business Executives and Startups, CONNECT Frameworks Workshop
    • November 6, 2013
      Technology Transfer: Adapting Models for BioInspired Success given at the San Diego Zoo's 4th Annual BioInspiration Conference
    • February 7, 2013
      Licensing Fundamentals for Business Executives and Startups, a CONNECT Frameworks Workshop
    • February 2, 2012
      Licensing Fundamentals for Business Executives and Startups
    • January 19, 2011
      Licensing Fundamentals for Business Executives and Startups
    • December 14, 2010
      Partnering Transactions for IP Development and Commercialization
    • August 12, 2010
      Licensing for Business Development Executives and Non-Licensing Attorneys
    • June 3, 2010
      Licensing Essentials Business Executives and Startups in the Life Sciences and Software Industries, a CONNECT Frameworks Workshop
    • January 20, 2010
      Licensing Essentials for Business Executives and Startups
    • January 14, 2010
      Transactions for Exploiting IP: Strategic Alternatives to M&A, Jones Day University
    • October 20, 2009
      Contentious IP Provisions in M&A and Licensing Transactions and Related Trends, CLE presentation
    • August 12, 2009
      Patents 101, Licensing and Exhaustion, CLE presentation
    • August 6, 2009
      The Latest on Current Big Ticket IP Issues: Obviousness and Patent Licensing/Exhaustion, ACCA San Diego Chapter, CLE presentation
    • June 10, 2009
      Fundamentals of Licensing Transactions - for Business Executives and Startups, CONNECT Frameworks Seminar
    • December 9, 2008
      Licensing Transactions in Life Sciences and Software for Business Executives, CONNECT Frameworks Seminar
    • February 5, 2008
      Fundamentals of Licensing in the Life Sciences, CONNECT Frameworks Seminar
    • February 15, 2007
      Fundamentals of Licensing in the Life Sciences, CONNECT Frameworks Seminar
    • December 11, 2006
      Advanced IP Support of M&A and Private Equity Transactions, CLE presentation
    • June 26, 2006
      Patents and Trade Secrets in the Food Industry, Annual Meeting of the Institute of Food Technologists
    • June 22, 2006
      World Class IP Practices: Management, Prosecution and Enforcement, CLE presentation
    • July 22, 2004
      Patents, Trade Secrets and Trademarks, CLE Presentation
    • February 25, 2004
      IP Licensing: Tips for the Taiwanese Semiconductor Industry, Taiwan Semiconductor Industry Association at the Industrial Technology Research Institute in the Science and Industrial Park
    • September 30, 2003
      IP Licensing: Tips for the Taiwan Semiconductor Industry, Taiwan Semiconductor Industry Association and ITRI
    • May 16, 2003
      Strategic Alternatives to Acquisitions, The 2003 Institute for Business Lawyers and Corporate Counsel
    • October 1, 2002
      IP and Technology Management, Taiwan Semiconductor Industry Association and National Taiwan University College of Law
    • November 12, 2001
      Learning from the Mistakes of the 90's, Tips on Licensing To and From Financially Troubled Companies

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.